Czech National Bank Acquires 9,641 Shares of Eli Lilly and Company $LLY

Czech National Bank boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 201,919 shares of the company’s stock after buying an additional 9,641 shares during the period. Eli Lilly and Company makes up approximately 1.1% of Czech National Bank’s holdings, making the stock its 12th biggest holding. Czech National Bank’s holdings in Eli Lilly and Company were worth $154,064,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company in the 1st quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company during the 2nd quarter worth about $27,000. Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company during the 2nd quarter worth about $29,000. Steph & Co. raised its stake in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company in the second quarter valued at about $31,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.4%

NYSE LLY opened at $1,056.57 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a 50 day moving average of $956.00 and a 200-day moving average of $828.10. The company has a market cap of $998.86 billion, a PE ratio of 51.69, a PEG ratio of 1.31 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the company earned $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 29.35%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Morgan Stanley increased their price objective on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Bank of America decreased their price target on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. Finally, Daiwa America raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,141.73.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.